New hope for tough brain cancer: Triple-Drug attack shows promise
NCT ID NCT05698147
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a three-drug combination (selinexor, methotrexate, and rituximab) in 30 adults with central nervous system lymphoma that has relapsed or not responded to treatment. The goal is to find the safest dose and see how well the combo works. Participants receive the drugs in cycles, and those who improve may continue maintenance therapy for up to a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selinexor (a drug that blocks a protein helping cancer cells survive), combined with methotrexate and rituximab (standard chemotherapy and targeted therapy)
What this could lead to
If successful, this could offer a new treatment option for people with central nervous system lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and the study is not designed to prove a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Hematology, Huashan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oncology Department of The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital Of Anhui Medical University
NOT_YET_RECRUITINGHefei, Anhui, China
Contact
-
The First Affiliated Hospital Of Fujian Medical University
NOT_YET_RECRUITINGFuzhou, Fujian, China
Contact